World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
40187
World Ranking
11579
National Ranking
5942

David G. Pfister publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David G. Pfister sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 502 publications — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David G. Pfister D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David G. Pfister sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David G. Pfister is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on medical fields with extensive work in oncology, surgery, pulmonary and respiratory medicine, otorhinolaryngology, and radiology, nuclear medicine, and imaging.

The main areas of study cover:

  • Medicine

Within these broad fields, the scientist's subfields of study include:

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Oncology
  • Otorhinolaryngology
  • Radiology, Nuclear Medicine and Imaging

The research topics addressed involve:

  • Head and Neck Cancer Studies
  • Head and Neck Surgical Oncology
  • Salivary Gland Tumors Diagnosis and Treatment
  • Cancer Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Prostate Cancer Diagnosis and Treatment

David G. Pfister has contributed to several recent papers, notably:

  • Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology (2020), published in Journal of the National Comprehensive Cancer Network
  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial (2021), published in The Lancet Oncology
  • NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022 (2022), published in Journal of the National Comprehensive Cancer Network
  • Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma (2020), published in Journal of Clinical Oncology
  • Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial (2020), published in JNCI Journal of the National Cancer Institute

Their frequent co-authors include:

  • Eric J. Sherman
  • Alan L. Ho
  • Lara Dunn
  • Richard J. Wong
  • Loren S. Michel

David G. Pfister's work has been published regularly in these venues:

  • Journal of Clinical Oncology
  • International Journal of Radiation Oncology*Biology*Physics
  • The Journal of Urology
  • Journal of the National Comprehensive Cancer Network
  • Oral Oncology

Best Publications

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003

    David G. Pfister;David H. Johnson;Christopher G. Azzoli;William Sause

  • Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin

    Jose Baselga;D. Pfister;M. R. Cooper;R. Cohen

  • Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*

    Abram Recht;Stephen B. Edge;Lawrence J. Solin;David S. Robinson

  • [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

    Christopher G. Azzoli;Sherman Baker;Sarah Temin;William Pao

  • Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

    David G. Pfister;Sharon Spencer;David Adelstein;Douglas Adkins

  • Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines

    Richard J. Gralla;David Osoba;Mark G. Kris;Peter Kirkbride

  • Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

    Alan L. Ho;Ravinder K. Grewal;Rebecca Leboeuf;Eric J. Sherman

  • Colorectal Cancer Surveillance: 2005 Update of an American Society of Clinical Oncology Practice Guideline

    Christopher E. Desch;Al B. Benson;Mark R. Somerfield;Patrick J. Flynn

  • Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

    Joshua Bauml;Tanguy Y. Seiwert;David G. Pfister;Francis Worden

  • Head and Neck Cancers, Version 2.2014

    David G. Pfister;Sharon Spencer;David M. Brizel;Barbara Burtness

  • American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer

    David G. Pfister;Scott A. Laurie;Gregory S. Weinstein;William M. Mendenhall

  • Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

    Razelle Kurzrock;Steven I. Sherman;Douglas W. Ball;Arlene A. Forastiere

  • Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

    Samuel A. Wells;Jessica E. Gosnell;Robert F. Gagel;Jeffrey Moley

  • Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the Memorial Sloan-Kettering experience

    Suzanne L. Wolden;William C. Chen;David G. Pfister;Dennis H. Kraus

  • NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018

    A. Dimitrios Colevas;Sue S. Yom;David G. Pfister;Sharon Spencer

  • American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer

    Bruce E. Hillner;James N. Ingle;James R. Berenson;Nora A. Janjan

  • Factors associated with complications in microvascular reconstruction of head and neck defects.

    Bhuvanesh Singh;Peter G. Cordeiro;Eric Santamaria;Ashok R. Shaha

  • American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.

    Martee L. Hensley;Lynn M. Schuchter;Celeste Lindley;Neal J. Meropol

  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

    Thomas Powles;Thomas Powles;Tibor Csőszi;Mustafa Özgüroğlu;Nobuaki Matsubara

Frequent Co-Authors

Nancy Y. Lee
Nancy Y. Lee Memorial Sloan Kettering Cancer Center
Jatin P. Shah
Jatin P. Shah Memorial Sloan Kettering Cancer Center
Dennis H. Kraus
Dennis H. Kraus Northwell Health
Michael J. Zelefsky
Michael J. Zelefsky Memorial Sloan Kettering Cancer Center
Axel Heidenreich
Axel Heidenreich University of Cologne
Ashok R. Shaha
Ashok R. Shaha Memorial Sloan Kettering Cancer Center
Suzanne L. Wolden
Suzanne L. Wolden Memorial Sloan Kettering Cancer Center
Richard J. Wong
Richard J. Wong Memorial Sloan Kettering Cancer Center
Louis B. Harrison
Louis B. Harrison Moffitt Cancer Center
Snehal G. Patel
Snehal G. Patel Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Aspiring medical professionals often explore diverse online degree options to advance their careers or change their specialization. One popular route is becoming a nurse, and there are multiple flexible paths available for both non-nurses and practicing RNs.

For those without a nursing background, direct entry msn programs for non-nursing majors online offer a fast-track into advanced nursing roles. Similarly, individuals looking for entry-level credentials can consider online adn programs for non nurses, providing a quicker entry point into the nursing profession.

Practicing RNs aiming to enhance their qualifications typically look for RN to BSN programs, but the average cost of rn to bsn programs is a key consideration when selecting the best option. For those seeking leadership or academic roles, an online phd in nursing delivers advanced expertise through flexible online study.

Whether advancing a current career or embarking on a new healthcare path, these online programs offer accessible and affordable ways to reach your goals in the field of medicine.

Best Scientists Citing David G. Pfister

Trending Scientists

Recently Published Articles